Se 2 Mo 10 V 3 , a heteropoly compound containing selenium, inhibits tumor growth.

Autor: Zhang HN; Department of Pharmacology, School of Basic Medical Sciences, Capital Medical University, Beijing 100069, China., Feng WL; Department of Pharmacology, School of Basic Medical Sciences, Qinghai University, Xining 810001, China., An CN; Department of Pharmacology, School of Basic Medical Sciences, North China University of Science and Technology, Tangshan 063009, China., Li WG; Department of Pharmacology, School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China.
Jazyk: angličtina
Zdroj: Oncotarget [Oncotarget] 2017 Jul 01; Vol. 8 (40), pp. 67871-67877. Date of Electronic Publication: 2017 Jul 01 (Print Publication: 2017).
DOI: 10.18632/oncotarget.18909
Abstrakt: Selenium compounds have strong anti-tumor effects and are well-tolerated. We examined the anti-tumor effects of (NH 4 ) 2 H 15 Se 2 VI Mo 10 V 3 O 52 ·2H 2 O (Se 2 Mo 10 V 3) , a heteropoly compound containing selenium. Se 2 Mo 10 V 3 inhibited proliferation in K562 cells with a half-maximal inhibitory concentration of 78.72±2.82 mg/L after 48 h and 24.94±0.88 mg/L after 72 h. Typical apoptotic morphologies were also observed in K562 cells treated with Se 2 Mo 10 V 3 , as were increased intracellular levels of Ca 2+ , Mg 2+ , H + , and reactive oxygen species, and decreased mitochondrial membrane potential. In addition, Se 2 Mo 10 V 3 treatment triggered cytochrome C release and inhibited IκBα degradation and NF-κB translocation. In vivo experiments revealed that 5 or 10 mg/kg Se 2 Mo 10 V 3 inhibited the growth of sarcoma 180 and hepatoma 22 xenograft tumors. These results indicate that Se 2 Mo 10 V 3 inhibits tumor growth both in vitro and in vivo and induces apoptosis in K562 cells, possibly by inhibiting the NF-κB/IκBα pathway.
Competing Interests: CONFLICTS OF INTEREST The authors declare no conflicts of interest.
Databáze: MEDLINE
Externí odkaz: